PMC:7187660 / 1636-2855 JSONTXT

{"project":"LitCovid-PD-MONDO","denotations":[{"id":"T13","span":{"begin":831,"end":843},"obj":"Disease"},{"id":"T14","span":{"begin":912,"end":920},"obj":"Disease"},{"id":"T15","span":{"begin":986,"end":1008},"obj":"Disease"},{"id":"T16","span":{"begin":1073,"end":1092},"obj":"Disease"},{"id":"T17","span":{"begin":1155,"end":1161},"obj":"Disease"}],"attributes":[{"id":"A13","pred":"mondo_id","subj":"T13","obj":"http://purl.obolibrary.org/obo/MONDO_0005044"},{"id":"A14","pred":"mondo_id","subj":"T14","obj":"http://purl.obolibrary.org/obo/MONDO_0005015"},{"id":"A15","pred":"mondo_id","subj":"T15","obj":"http://purl.obolibrary.org/obo/MONDO_0004995"},{"id":"A16","pred":"mondo_id","subj":"T16","obj":"http://purl.obolibrary.org/obo/MONDO_0005087"},{"id":"A17","pred":"mondo_id","subj":"T17","obj":"http://purl.obolibrary.org/obo/MONDO_0004992"}],"text":"Characteristics Total (n = 44,672) Non-survivors (n = 1023) Survivors (n = 43,649) Fatality (%) RR (95%CI) p\nAge, n (%)\n 0– 416 (0.9%) 0 416 (0.9%) 0\n 10– 549 (1.2%) 1 (0.1%) 548 (1.3%) 0.2\n 20– 3619 (8.1%) 7 (0.7%) 3612 (8.3%) 0.2\n 30– 7600 (17.0%) 18 (1.8%) 7582 (17.4%) 0.2\n 40– 8571 (19.2%) 38 (3.7%) 8533 (19.5%) 0.4\n 50– 10,008 (22.4%) 130 (12.7%) 9878 (22.6%) 1.3\n 60– 8583 (19.2%) 309 (30.2%) 8274 (19.0%) 3.6\n 70– 3918 (8.8%) 312 (30.5%) 3606 (8.3%) 8.0\n ≥ 80 1408 (3.2%) 208 (20.3%) 1200 (2.7%) 14.8\nSeverity*, n (%)\n Mild/moderate 36,160 (80.9%) 0 36,160 (82.8%) 0\n Severe 6168 (13.8%) 0 6168 (14.1%) 0\n Critical 2087 (4.7%) 1023 (100%) 1064 (2.4%) 49.0\nGender, n (%)\n Male 22,981 (51.4%) 653 (63.8%) 22,328 (51.2%) 2.8 1.67 (1.47–1.89) \u003c 0.001\n Female 21,691 (48.6%) 370 (36.2%) 21,321 (48.8%) 1.7\nComorbidity#, n (%)\n Hypertension 2683 (12.8%) 161 (39.7%) 2522 (12.3%) 6.0 4.48 (3.69–5.45) \u003c 0.001\n Diabetes 1102 (5.3%) 80 (19.7%) 1022 (5.0%) 7.3 4.47 (3.49–5.61) \u003c 0.001\n Cardiovascular disease 873 (4.2%) 92 (22.7%) 781 (3.8%) 10.5 6.75 (5.40–8.43) \u003c 0.001\n Respiratory disease 511 (2.4%) 32 (7.9%) 479 (2.3%) 6.3 3.43 (2.42–4.87) \u003c 0.001\n Cancer 107 (0.5%) 6 (1.5%) 101 (0.5%) 5.6 2.93 (1.34–6.41) 0.006"}

{"project":"LitCovid-PD-CLO","denotations":[{"id":"T9","span":{"begin":175,"end":178},"obj":"http://purl.obolibrary.org/obo/CLO_0001414"},{"id":"T10","span":{"begin":250,"end":252},"obj":"http://purl.obolibrary.org/obo/CLO_0050510"},{"id":"T11","span":{"begin":680,"end":684},"obj":"http://purl.obolibrary.org/obo/UBERON_0003101"},{"id":"T12","span":{"begin":680,"end":684},"obj":"http://www.ebi.ac.uk/efo/EFO_0000970"},{"id":"T13","span":{"begin":757,"end":763},"obj":"http://purl.obolibrary.org/obo/UBERON_0003100"},{"id":"T14","span":{"begin":1093,"end":1096},"obj":"http://purl.obolibrary.org/obo/CLO_0001405"}],"text":"Characteristics Total (n = 44,672) Non-survivors (n = 1023) Survivors (n = 43,649) Fatality (%) RR (95%CI) p\nAge, n (%)\n 0– 416 (0.9%) 0 416 (0.9%) 0\n 10– 549 (1.2%) 1 (0.1%) 548 (1.3%) 0.2\n 20– 3619 (8.1%) 7 (0.7%) 3612 (8.3%) 0.2\n 30– 7600 (17.0%) 18 (1.8%) 7582 (17.4%) 0.2\n 40– 8571 (19.2%) 38 (3.7%) 8533 (19.5%) 0.4\n 50– 10,008 (22.4%) 130 (12.7%) 9878 (22.6%) 1.3\n 60– 8583 (19.2%) 309 (30.2%) 8274 (19.0%) 3.6\n 70– 3918 (8.8%) 312 (30.5%) 3606 (8.3%) 8.0\n ≥ 80 1408 (3.2%) 208 (20.3%) 1200 (2.7%) 14.8\nSeverity*, n (%)\n Mild/moderate 36,160 (80.9%) 0 36,160 (82.8%) 0\n Severe 6168 (13.8%) 0 6168 (14.1%) 0\n Critical 2087 (4.7%) 1023 (100%) 1064 (2.4%) 49.0\nGender, n (%)\n Male 22,981 (51.4%) 653 (63.8%) 22,328 (51.2%) 2.8 1.67 (1.47–1.89) \u003c 0.001\n Female 21,691 (48.6%) 370 (36.2%) 21,321 (48.8%) 1.7\nComorbidity#, n (%)\n Hypertension 2683 (12.8%) 161 (39.7%) 2522 (12.3%) 6.0 4.48 (3.69–5.45) \u003c 0.001\n Diabetes 1102 (5.3%) 80 (19.7%) 1022 (5.0%) 7.3 4.47 (3.49–5.61) \u003c 0.001\n Cardiovascular disease 873 (4.2%) 92 (22.7%) 781 (3.8%) 10.5 6.75 (5.40–8.43) \u003c 0.001\n Respiratory disease 511 (2.4%) 32 (7.9%) 479 (2.3%) 6.3 3.43 (2.42–4.87) \u003c 0.001\n Cancer 107 (0.5%) 6 (1.5%) 101 (0.5%) 5.6 2.93 (1.34–6.41) 0.006"}

{"project":"LitCovid-PD-CHEBI","denotations":[{"id":"T7","span":{"begin":96,"end":98},"obj":"Chemical"}],"attributes":[{"id":"A7","pred":"chebi_id","subj":"T7","obj":"http://purl.obolibrary.org/obo/CHEBI_73811"}],"text":"Characteristics Total (n = 44,672) Non-survivors (n = 1023) Survivors (n = 43,649) Fatality (%) RR (95%CI) p\nAge, n (%)\n 0– 416 (0.9%) 0 416 (0.9%) 0\n 10– 549 (1.2%) 1 (0.1%) 548 (1.3%) 0.2\n 20– 3619 (8.1%) 7 (0.7%) 3612 (8.3%) 0.2\n 30– 7600 (17.0%) 18 (1.8%) 7582 (17.4%) 0.2\n 40– 8571 (19.2%) 38 (3.7%) 8533 (19.5%) 0.4\n 50– 10,008 (22.4%) 130 (12.7%) 9878 (22.6%) 1.3\n 60– 8583 (19.2%) 309 (30.2%) 8274 (19.0%) 3.6\n 70– 3918 (8.8%) 312 (30.5%) 3606 (8.3%) 8.0\n ≥ 80 1408 (3.2%) 208 (20.3%) 1200 (2.7%) 14.8\nSeverity*, n (%)\n Mild/moderate 36,160 (80.9%) 0 36,160 (82.8%) 0\n Severe 6168 (13.8%) 0 6168 (14.1%) 0\n Critical 2087 (4.7%) 1023 (100%) 1064 (2.4%) 49.0\nGender, n (%)\n Male 22,981 (51.4%) 653 (63.8%) 22,328 (51.2%) 2.8 1.67 (1.47–1.89) \u003c 0.001\n Female 21,691 (48.6%) 370 (36.2%) 21,321 (48.8%) 1.7\nComorbidity#, n (%)\n Hypertension 2683 (12.8%) 161 (39.7%) 2522 (12.3%) 6.0 4.48 (3.69–5.45) \u003c 0.001\n Diabetes 1102 (5.3%) 80 (19.7%) 1022 (5.0%) 7.3 4.47 (3.49–5.61) \u003c 0.001\n Cardiovascular disease 873 (4.2%) 92 (22.7%) 781 (3.8%) 10.5 6.75 (5.40–8.43) \u003c 0.001\n Respiratory disease 511 (2.4%) 32 (7.9%) 479 (2.3%) 6.3 3.43 (2.42–4.87) \u003c 0.001\n Cancer 107 (0.5%) 6 (1.5%) 101 (0.5%) 5.6 2.93 (1.34–6.41) 0.006"}

{"project":"LitCovid-sentences","denotations":[{"id":"T11","span":{"begin":0,"end":108},"obj":"Sentence"},{"id":"T12","span":{"begin":109,"end":119},"obj":"Sentence"},{"id":"T13","span":{"begin":120,"end":149},"obj":"Sentence"},{"id":"T14","span":{"begin":150,"end":189},"obj":"Sentence"},{"id":"T15","span":{"begin":190,"end":231},"obj":"Sentence"},{"id":"T16","span":{"begin":232,"end":276},"obj":"Sentence"},{"id":"T17","span":{"begin":277,"end":321},"obj":"Sentence"},{"id":"T18","span":{"begin":322,"end":370},"obj":"Sentence"},{"id":"T19","span":{"begin":371,"end":417},"obj":"Sentence"},{"id":"T20","span":{"begin":418,"end":462},"obj":"Sentence"},{"id":"T21","span":{"begin":463,"end":509},"obj":"Sentence"},{"id":"T22","span":{"begin":510,"end":526},"obj":"Sentence"},{"id":"T23","span":{"begin":527,"end":575},"obj":"Sentence"},{"id":"T24","span":{"begin":576,"end":613},"obj":"Sentence"},{"id":"T25","span":{"begin":614,"end":664},"obj":"Sentence"},{"id":"T26","span":{"begin":665,"end":678},"obj":"Sentence"},{"id":"T27","span":{"begin":679,"end":755},"obj":"Sentence"},{"id":"T28","span":{"begin":756,"end":809},"obj":"Sentence"},{"id":"T29","span":{"begin":810,"end":829},"obj":"Sentence"},{"id":"T30","span":{"begin":830,"end":910},"obj":"Sentence"},{"id":"T31","span":{"begin":911,"end":984},"obj":"Sentence"},{"id":"T32","span":{"begin":985,"end":1071},"obj":"Sentence"},{"id":"T33","span":{"begin":1072,"end":1153},"obj":"Sentence"},{"id":"T34","span":{"begin":1154,"end":1219},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"Characteristics Total (n = 44,672) Non-survivors (n = 1023) Survivors (n = 43,649) Fatality (%) RR (95%CI) p\nAge, n (%)\n 0– 416 (0.9%) 0 416 (0.9%) 0\n 10– 549 (1.2%) 1 (0.1%) 548 (1.3%) 0.2\n 20– 3619 (8.1%) 7 (0.7%) 3612 (8.3%) 0.2\n 30– 7600 (17.0%) 18 (1.8%) 7582 (17.4%) 0.2\n 40– 8571 (19.2%) 38 (3.7%) 8533 (19.5%) 0.4\n 50– 10,008 (22.4%) 130 (12.7%) 9878 (22.6%) 1.3\n 60– 8583 (19.2%) 309 (30.2%) 8274 (19.0%) 3.6\n 70– 3918 (8.8%) 312 (30.5%) 3606 (8.3%) 8.0\n ≥ 80 1408 (3.2%) 208 (20.3%) 1200 (2.7%) 14.8\nSeverity*, n (%)\n Mild/moderate 36,160 (80.9%) 0 36,160 (82.8%) 0\n Severe 6168 (13.8%) 0 6168 (14.1%) 0\n Critical 2087 (4.7%) 1023 (100%) 1064 (2.4%) 49.0\nGender, n (%)\n Male 22,981 (51.4%) 653 (63.8%) 22,328 (51.2%) 2.8 1.67 (1.47–1.89) \u003c 0.001\n Female 21,691 (48.6%) 370 (36.2%) 21,321 (48.8%) 1.7\nComorbidity#, n (%)\n Hypertension 2683 (12.8%) 161 (39.7%) 2522 (12.3%) 6.0 4.48 (3.69–5.45) \u003c 0.001\n Diabetes 1102 (5.3%) 80 (19.7%) 1022 (5.0%) 7.3 4.47 (3.49–5.61) \u003c 0.001\n Cardiovascular disease 873 (4.2%) 92 (22.7%) 781 (3.8%) 10.5 6.75 (5.40–8.43) \u003c 0.001\n Respiratory disease 511 (2.4%) 32 (7.9%) 479 (2.3%) 6.3 3.43 (2.42–4.87) \u003c 0.001\n Cancer 107 (0.5%) 6 (1.5%) 101 (0.5%) 5.6 2.93 (1.34–6.41) 0.006"}

{"project":"LitCovid-PD-HP","denotations":[{"id":"T3","span":{"begin":831,"end":843},"obj":"Phenotype"},{"id":"T4","span":{"begin":986,"end":1008},"obj":"Phenotype"},{"id":"T5","span":{"begin":1155,"end":1161},"obj":"Phenotype"}],"attributes":[{"id":"A3","pred":"hp_id","subj":"T3","obj":"http://purl.obolibrary.org/obo/HP_0000822"},{"id":"A4","pred":"hp_id","subj":"T4","obj":"http://purl.obolibrary.org/obo/HP_0001626"},{"id":"A5","pred":"hp_id","subj":"T5","obj":"http://purl.obolibrary.org/obo/HP_0002664"}],"text":"Characteristics Total (n = 44,672) Non-survivors (n = 1023) Survivors (n = 43,649) Fatality (%) RR (95%CI) p\nAge, n (%)\n 0– 416 (0.9%) 0 416 (0.9%) 0\n 10– 549 (1.2%) 1 (0.1%) 548 (1.3%) 0.2\n 20– 3619 (8.1%) 7 (0.7%) 3612 (8.3%) 0.2\n 30– 7600 (17.0%) 18 (1.8%) 7582 (17.4%) 0.2\n 40– 8571 (19.2%) 38 (3.7%) 8533 (19.5%) 0.4\n 50– 10,008 (22.4%) 130 (12.7%) 9878 (22.6%) 1.3\n 60– 8583 (19.2%) 309 (30.2%) 8274 (19.0%) 3.6\n 70– 3918 (8.8%) 312 (30.5%) 3606 (8.3%) 8.0\n ≥ 80 1408 (3.2%) 208 (20.3%) 1200 (2.7%) 14.8\nSeverity*, n (%)\n Mild/moderate 36,160 (80.9%) 0 36,160 (82.8%) 0\n Severe 6168 (13.8%) 0 6168 (14.1%) 0\n Critical 2087 (4.7%) 1023 (100%) 1064 (2.4%) 49.0\nGender, n (%)\n Male 22,981 (51.4%) 653 (63.8%) 22,328 (51.2%) 2.8 1.67 (1.47–1.89) \u003c 0.001\n Female 21,691 (48.6%) 370 (36.2%) 21,321 (48.8%) 1.7\nComorbidity#, n (%)\n Hypertension 2683 (12.8%) 161 (39.7%) 2522 (12.3%) 6.0 4.48 (3.69–5.45) \u003c 0.001\n Diabetes 1102 (5.3%) 80 (19.7%) 1022 (5.0%) 7.3 4.47 (3.49–5.61) \u003c 0.001\n Cardiovascular disease 873 (4.2%) 92 (22.7%) 781 (3.8%) 10.5 6.75 (5.40–8.43) \u003c 0.001\n Respiratory disease 511 (2.4%) 32 (7.9%) 479 (2.3%) 6.3 3.43 (2.42–4.87) \u003c 0.001\n Cancer 107 (0.5%) 6 (1.5%) 101 (0.5%) 5.6 2.93 (1.34–6.41) 0.006"}

{"project":"LitCovid-PMC-OGER-BB","denotations":[{"id":"T13","span":{"begin":986,"end":1000},"obj":"UBERON:0004535"},{"id":"T38161","span":{"begin":986,"end":1000},"obj":"UBERON:0004535"}],"text":"Characteristics Total (n = 44,672) Non-survivors (n = 1023) Survivors (n = 43,649) Fatality (%) RR (95%CI) p\nAge, n (%)\n 0– 416 (0.9%) 0 416 (0.9%) 0\n 10– 549 (1.2%) 1 (0.1%) 548 (1.3%) 0.2\n 20– 3619 (8.1%) 7 (0.7%) 3612 (8.3%) 0.2\n 30– 7600 (17.0%) 18 (1.8%) 7582 (17.4%) 0.2\n 40– 8571 (19.2%) 38 (3.7%) 8533 (19.5%) 0.4\n 50– 10,008 (22.4%) 130 (12.7%) 9878 (22.6%) 1.3\n 60– 8583 (19.2%) 309 (30.2%) 8274 (19.0%) 3.6\n 70– 3918 (8.8%) 312 (30.5%) 3606 (8.3%) 8.0\n ≥ 80 1408 (3.2%) 208 (20.3%) 1200 (2.7%) 14.8\nSeverity*, n (%)\n Mild/moderate 36,160 (80.9%) 0 36,160 (82.8%) 0\n Severe 6168 (13.8%) 0 6168 (14.1%) 0\n Critical 2087 (4.7%) 1023 (100%) 1064 (2.4%) 49.0\nGender, n (%)\n Male 22,981 (51.4%) 653 (63.8%) 22,328 (51.2%) 2.8 1.67 (1.47–1.89) \u003c 0.001\n Female 21,691 (48.6%) 370 (36.2%) 21,321 (48.8%) 1.7\nComorbidity#, n (%)\n Hypertension 2683 (12.8%) 161 (39.7%) 2522 (12.3%) 6.0 4.48 (3.69–5.45) \u003c 0.001\n Diabetes 1102 (5.3%) 80 (19.7%) 1022 (5.0%) 7.3 4.47 (3.49–5.61) \u003c 0.001\n Cardiovascular disease 873 (4.2%) 92 (22.7%) 781 (3.8%) 10.5 6.75 (5.40–8.43) \u003c 0.001\n Respiratory disease 511 (2.4%) 32 (7.9%) 479 (2.3%) 6.3 3.43 (2.42–4.87) \u003c 0.001\n Cancer 107 (0.5%) 6 (1.5%) 101 (0.5%) 5.6 2.93 (1.34–6.41) 0.006"}

{"project":"LitCovid-PubTator","denotations":[{"id":"17","span":{"begin":831,"end":843},"obj":"Disease"},{"id":"18","span":{"begin":912,"end":920},"obj":"Disease"},{"id":"19","span":{"begin":986,"end":1008},"obj":"Disease"},{"id":"20","span":{"begin":1073,"end":1092},"obj":"Disease"},{"id":"21","span":{"begin":1155,"end":1161},"obj":"Disease"}],"attributes":[{"id":"A17","pred":"tao:has_database_id","subj":"17","obj":"MESH:D006973"},{"id":"A18","pred":"tao:has_database_id","subj":"18","obj":"MESH:D003920"},{"id":"A19","pred":"tao:has_database_id","subj":"19","obj":"MESH:D002318"},{"id":"A20","pred":"tao:has_database_id","subj":"20","obj":"MESH:D012140"},{"id":"A21","pred":"tao:has_database_id","subj":"21","obj":"MESH:D009369"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"Characteristics Total (n = 44,672) Non-survivors (n = 1023) Survivors (n = 43,649) Fatality (%) RR (95%CI) p\nAge, n (%)\n 0– 416 (0.9%) 0 416 (0.9%) 0\n 10– 549 (1.2%) 1 (0.1%) 548 (1.3%) 0.2\n 20– 3619 (8.1%) 7 (0.7%) 3612 (8.3%) 0.2\n 30– 7600 (17.0%) 18 (1.8%) 7582 (17.4%) 0.2\n 40– 8571 (19.2%) 38 (3.7%) 8533 (19.5%) 0.4\n 50– 10,008 (22.4%) 130 (12.7%) 9878 (22.6%) 1.3\n 60– 8583 (19.2%) 309 (30.2%) 8274 (19.0%) 3.6\n 70– 3918 (8.8%) 312 (30.5%) 3606 (8.3%) 8.0\n ≥ 80 1408 (3.2%) 208 (20.3%) 1200 (2.7%) 14.8\nSeverity*, n (%)\n Mild/moderate 36,160 (80.9%) 0 36,160 (82.8%) 0\n Severe 6168 (13.8%) 0 6168 (14.1%) 0\n Critical 2087 (4.7%) 1023 (100%) 1064 (2.4%) 49.0\nGender, n (%)\n Male 22,981 (51.4%) 653 (63.8%) 22,328 (51.2%) 2.8 1.67 (1.47–1.89) \u003c 0.001\n Female 21,691 (48.6%) 370 (36.2%) 21,321 (48.8%) 1.7\nComorbidity#, n (%)\n Hypertension 2683 (12.8%) 161 (39.7%) 2522 (12.3%) 6.0 4.48 (3.69–5.45) \u003c 0.001\n Diabetes 1102 (5.3%) 80 (19.7%) 1022 (5.0%) 7.3 4.47 (3.49–5.61) \u003c 0.001\n Cardiovascular disease 873 (4.2%) 92 (22.7%) 781 (3.8%) 10.5 6.75 (5.40–8.43) \u003c 0.001\n Respiratory disease 511 (2.4%) 32 (7.9%) 479 (2.3%) 6.3 3.43 (2.42–4.87) \u003c 0.001\n Cancer 107 (0.5%) 6 (1.5%) 101 (0.5%) 5.6 2.93 (1.34–6.41) 0.006"}